secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2022-06-07T23:59:59+00:00
Accession:  0001193125-22-168911
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences appoints Dr. Hubert Chen as President and CSO
---------------------------------------------------------------

- Dr. Chen appointed President and Chief Scientific Officer effective June 7, 2022; Paul Wagner remains CEO.
- Annual base salary of $450,000, target annual bonus of 40% of base salary, and option for 250,000 shares.
- Dr. Chen previously served as CMO of Metacrine and CSO/CMO of Pfenex, leading PF708 NDA and MAA approvals.
- Options vest 25% after one year, remaining monthly over 36 months; grant under 2020 Inducement Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522168911/0001193125-22-168911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522168911/d274694d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-168911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer